This study aims to investigate safety and efficacy of Echinaforce Junior tablets in two dosages of 3 x 1 and 5 x 1 tablets per day in children 4 - 12 years old with acute colds.
Study Type
OBSERVATIONAL
Enrollment
79
Dr. med. Arnold Bächler Facharzt FMH für Kinder- und Jugendmedizin
Sankt Gallen, Canton of St. Gallen, Switzerland
tolerability assessment by physicians
Within the observation period of 4 months a maximum of 3 colds can be treated with Echinaforce Junior tablets at the indicated dosage. At the exclusion visit the physicians rate the tolerability of Echinaforce Junior tablets as "very good", "good", "moderate" or "bad"
Time frame: 4 months
tolerability assessment by parents/child
The tolerability of Echinaforce Junior is assessed after every acute treatment period of 10 days and after the observation period of 4 months
Time frame: 4 months
tolerability assessment by parents/child
The tolerability of Echinaforce Junior is assessed after every acute treatment period of 10 days and after the observation period of 4 months
Time frame: 10 days
Assessment of efficacy by parents/child
The acute efficacy of Echinaforce Junior is rated by the parents after every acute treatment period of 10 days as well as after the observation period of 4 months
Time frame: 4 months
Assessment of Cold Symptoms during Acute Treatment
During acute colds parents complete a symptom diary and assess cold-related symptoms (runny and congested nose, sneezing, headache, joint pain, sore-throat, fever, cough, shivering, sleep quality, additional care) in the child
Time frame: 10 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.